RLM Realm Thera.

TIDMRLM

RNS Number : 3760A

Realm Therapeutics PLC

23 March 2017

Realm Therapeutics plc

("Realm Therapeutics" or the "Company")

Annual Report and Accounts Available

23 March 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, confirms that, further to the announcement of its Final Results today, an electronic copy of the Annual Report and Accounts for the year ended 31 December 2016 is now available on the Company's website, www.realmtx.com.

Enquiries:

 
                                      +44 (0) 20 3727 
 Realm Therapeutics plc                1000 
 Alex Martin, Chief Executive 
  Officer 
  Marella Thorell, Chief Financial 
  Officer and Chief Operating 
  Officer 
 
                                      +44 (0) 20 3727 
 FTI Consulting                        1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser        +44 (0) 20 7496 
  & Broker)                            3000 
 Aubrey Powell / Lauren Kettle 
 

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSLLFESVSIVFID

(END) Dow Jones Newswires

March 23, 2017 10:57 ET (14:57 GMT)

Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024

Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024